Form DEFA14A Intra-Cellular Therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
January 13, 2025 9:54 AM ESTMorgan Stanley analyst Jeffrey Hung downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Equalweight with a price target of $132.00 (from $102.00).
The analyst comments "JNJ announced this morning that it has entered into an agreement to acquire Intra-Cellular Therapies for $132/share. We downgrade... More
